← 프로그램 목록
세포·유전자 치료Phase 1Active

CRISPR/Cas9

Allife Medical ScienceTechnology Co.Ltd.

비교

CRISPR/Cas9(Allife Medical Science and Technology Co., Ltd.)은 Human Papillomavirus-Related Malignant N 표적 세포·유전자 치료로, Human Papillomavirus-Related Malignant Neoplasm 영역에서 개발·상용화 중입니다. 작용기전: targets with improved tissue restriction; (2) architectural innovations such as armored CARs, optimized signaling (1XX, 28-ΔIL2RB-z(YXXQ)), and cytokine-arming; (3) combinato. Phase 1 안전성·PK 탐색 단계입니다. 대표 임상 효능: ORR 25% (ClinicalTrials.gov NCT04035434). 차별점: novel link between intracellular cholesterol metabolism and vascular growth.

출처: ClinicalTrials.gov · PubMed · openFDA최근 동기화됨

개요

임상 2026년 7월 13일 (1일 전)PK/독성 2026년 7월 13일 (1일 전)

Human Papillomavirus-Related Malignant N

Human Papillomavirus-Related Malignant Neoplasm

Active

Technology

구조모아 · StructureMoa에서 구조 검색

CAR-T engineering for colorectal cancer: integrating targets, tum

s

retroviral therapies suppress HIV replication but fail to eliminate integrated proviral DN

humanized mice, CD4-NBs significantly reduced plasma viremia

novel link between intracellular cholesterol metabolism and vascular growth

Mechanism of Action

targets with improved tissue restriction; (2) architectural innovations such as armored CARs, optimized signaling (1XX, 28-ΔIL2RB-z(YXXQ)), and cytokine-arming; (3) combinatorial antigen

macrophages, we engineered a novel trispecific macrophage engager (TriME) designed for simultaneous engagement

payloads and remodel the tumor microenvironment; in infectious diseases, they enhance pathogen clearance; and in autoimmune dis

PD-L1 therapy, reduced CD8 + T-cell infiltration, and attenuated MHC-I expression

resistance to GA-DM, disruption of genes involved in ubiquitin-mediated proteolysis and the Hippo pathway sensitised cells to GA-DM

임상시험 & 결과

차트 로드 중…

임상 한눈에 보기

  • 50건의 ClinicalTrials.gov 임상 기록
  • Phase·Status 요약은 enrollment 상위 표본 기준입니다
  • 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
  • Phase: Phase 3 · Phase 1, Phase 2 · Phase 1 · Phase 2, Phase 3
  • Status: Recruiting · Unknown status · Terminated
  • 주요 endpoint: Composite outcome of cardiovascular (CV) mortality and CV events · Change in baseline to month 18 in serum TTR · Change from baseline to month 18 in KCCQ-OS score · Identification of a specific acetylation profile of RSTS · Identification of different target genes between SRT patients and controls
  • 등록된 결과: ORR 25%
  • 핵심: This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX110 in subjects with relaps…

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.

참고문헌

자주 묻는 질문

CRISPR/Cas9은 어떤 치료제인가요?
CRISPR/Cas9(Allife Medical Science and Technology Co., Ltd.)은 Human Papillomavirus-Related Malignant N 표적 세포·유전자 치료로, Human Papillomavirus-Related Malignant Neoplasm 영역에서 개발·상용화 중입니다. 데이터는 바이오모아 (BioMoa)에서 ClinicalTrials.gov·openFDA·PubMed 기반으로 정리합니다.
CRISPR/Cas9의 임상 단계는?
CRISPR/Cas9의 현재 단계는 Phase 1입니다.
비슷한 프로그램과 어떻게 비교하나요?
바이오모아 (BioMoa) 비교 페이지에서 PK/PD, 독성, 임상 효능 지표를 나란히 볼 수 있습니다. 동일 타깃·모달리티 프리셋을 함께 참고하세요.